NCT07311330RecruitingPhase 2
A Randomized, Double-blind, Placebo-controlled Phase IIa Clinical Trial to Evaluate the Efficacy and Safety of YN001 in Patients With Atherosclerotic Cardiovascular and Cerebrovascular Diseases and Erectile Dysfunction
Beijing Inno Medicine Co., Ltd.1 site in 1 country40 target enrollmentStarted: February 4, 2026Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Recruiting
- Enrollment
- 40
- Locations
- 1
- Primary Endpoint
- Change from baseline in IIEF-EF (Questions 1-5 and 15 in the IIEF scale) score at Week 13 visit;
Study Overview
Brief Summary
This is a randomized, double-blind, placebo-controlled phase IIa clinical trial to evaluate the efficacy and safety of YN001 in patients with atherosclerotic cardiovascular and cerebrovascular diseases and erectile dysfunction
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to 75 Years (Adult, Older Adult)
- Sex
- Male
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Fully understand the purpose, nature, method and possible adverse reactions of the study, voluntarily participate as a subject in the study, and sign the informed consent form (ICF) before performing any study-related assessments;
- •One or both of the previous history of coronary atherosclerosis, coronary heart disease, cerebral atherosclerosis, stroke, ischemic attack, carotid atherosclerosis, peripheral arterial disease, or plaque in at least one vessel of the carotid, subclavian, or femoral arteries as detected by peripheral arterial ultrasound .
- •Clinical diagnosis of mild to moderate erectile dysfunction, IIEF-5 questionnaire score ≤ 21 points, duration of at least 3 months (subject to signing informed consent);
- •Subjects (including partners) guarantee that they have no plans to father a child or donate sperm during the study and for 3 months after the last dose and voluntarily take appropriate contraceptive measures;
- •After the screening run-in period, the following three conditions were met simultaneously:
- •1) At least 4 attempts at sexual intercourse during the run-in period; 2) Has a failure rate of ≥ 50% of attempts to intercourse (failure to intercourse is defined as having at least one of the three questions answered on the SEP); 3) IIEF-EF score ≥ 11 and ≤ 25.
Exclusion Criteria
- •Patients with erectile dysfunction caused by other sexual dysfunction diseases (such as ejaculatory dysfunction) or endocrine diseases that are not controlled (after medication) (such as hypogonadism, hyperthyroidism/hypothyroidism, pituitary tumor, etc.);
- •History of stroke within 6 months prior to informed consent;
- •Patients who have received or are receiving anti-androgen therapy, or have a history of androgen replacement therapy and are stable for less than 3 months;
- •Patients scheduled for CABG, PCI, heart transplantation, SAVR/TAVR during the study period;
- •Patients with unstable diabetic blood glucose control, and fasting blood glucose more than 15 mmol/L, or accompanied by diabetic complications (diabetic nephropathy, peripheral neuropathy);
- •Combined with abnormal liver function, defined as AST and/or ALT more than 2 times the upper limit of normal;
- •Combined with severe renal dysfunction, defined as glomerular filtration rate < 30.0 mL/min/1.73m ² calculated by CKD-EPI formula;
- •Subjects who have used vacuum aspiration (VCD), intracavernosal injection (ICI) therapy or other drugs to treat erectile dysfunction and cannot interrupt the above treatment during the study;
- •Patients who have severe central nervous system injury (cerebral vascular diseases such as cerebral hemorrhage or ischemia, brain inflammatory diseases such as encephalitis or meningitis, craniocerebral trauma or spinal cord injury), or peripheral nervous system injury or lesions within 6 months before signing the informed consent;
- •History of myopathy/myalgia, or susceptibility to myopathy/rhabdomyolysis (e.g., family history of hereditary myopathy, previous use of HMG-CoA reductase inhibitors in combination with fibrates, etc.);
- •Presenting with hypothyroidism, defined as marked TSH elevations (usually > 1.5 ULN) associated with decreases in free T4 (FT4) ;
- •Patients with a history of drug abuse, drug abuse and alcoholism (tolerance, withdrawal, impaired control of drinking behavior) in the past 1 year;
- •Participation in another interventional clinical investigator within 1 month prior to informed consent;
- •Patients who, in the opinion of the investigator, are not suitable for this study.
Arms & Interventions
YN001 20mg Dose + 5% glucose injection
Active Comparator
Specified dose on specified Days
Intervention: YN001 20mg Dose + 5% glucose injection (Drug)
5% glucose injection
Placebo Comparator
Specified dose on specified Days
Intervention: 5% glucose injection (Other)
Outcomes
Primary Outcomes
Change from baseline in IIEF-EF (Questions 1-5 and 15 in the IIEF scale) score at Week 13 visit;
Time Frame: 12 weeks
Change From Baseline in Carotid Artery Intima-media Thickness (IMT) by Peripheral Ultrasound at Week 13 Visit.
Time Frame: 12 weeks
Secondary Outcomes
- Adverse event (AE)/serious adverse event (SAE);(16 weeks)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Recruiting
Phase 2
Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes MellitusType II Diabetes MellitusNCT07282743Sun Pharmaceutical Industries Limited285
Recruiting
Phase 2
Topical Ketotifen 0.25% for Secondary VestibulodyniaProvoked VestibulodyniaSecondary Provoked VestibulodyniaNeuroproliferative VestibulodyniaVulvodyniaVulvary Pain DisordersMast Cell-mediated NeuroinflammationInstertional DyspareuniaNCT07257029Center for Vulvovaginal Disorders54
Recruiting
Phase 2
A Study of SHR-2173 in Participants With Systemic Lupus ErythematosusSystemic Lupus ErythematosusNCT07299422Guangdong Hengrui Pharmaceutical Co., Ltd248
Not yet recruiting
Phase 1
A Clinical Trial of AK152 in Healthy Volunteers and Patients With Alzheimer' s DiseaseAlzheimer' s DiseaseNCT07301502Akeso108
Recruiting
Phase 2
A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)Focal Segmental GlomerulosclerosisNCT07268638Akebia Therapeutics60